Z-Endoxifen HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561177

CAS#: 1032008-74-4

Description: Z-Endoxifen HCl is an estrogen receptor alpha (ERalpha) ligand, potent antiestrogen, and metabolite of tamoxifen. Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6.

Price and Availability




Z-Endoxifen HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 561177
Name: Z-Endoxifen HCl
CAS#: 1032008-74-4
Chemical Formula: C25H28ClNO2
Exact Mass:
Molecular Weight: 409.954
Elemental Analysis: C, 73.25; H, 6.88; Cl, 8.65; N, 3.42; O, 7.81

Synonym: Z-Endoxifen HCl; Z Endoxifen HCl; ZEndoxifen HCl; Z Endoxifen Hydrochloride; ZEndoxifen Hydrochloride

IUPAC/Chemical Name: 4-[(Z)-1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol hydrochloride


InChi Code: InChI=1S/C25H27NO2.ClH/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2;/h4-16,26-27H,3,17-18H2,1-2H3;1H/b25-24-;


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011 Oct;90(4):605-11. doi: 10.1038/clpt.2011.153. Epub 2011 Sep 7. PubMed PMID: 21900890.

2: Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel KA, Ton A, Turkbey B, Jacobs PM, Bhattacharyya S, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg ML. Utility of (18)F-fluoroestradiol ((18)F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):500-508. doi: 10.1007/s00259-016-3561-8. Epub 2016 Nov 21. PubMed PMID: 27872957.

3: de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring. Ther Drug Monit. 2017 Apr;39(2):132-137. doi: 10.1097/FTD.0000000000000372. PubMed PMID: 28045782.

4: Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. doi: 10.1007/s00280-014-2605-7. Epub 2014 Oct 16. PubMed PMID: 25318936; PubMed Central PMCID: PMC4343319.

5: Ding S, Bierbach U. Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents. Dalton Trans. 2016 Aug 16;45(33):13104-13. doi: 10.1039/c6dt01399f. PubMed PMID: 27251881; PubMed Central PMCID: PMC4987242.